Annual report pursuant to Section 13 and 15(d)

Aytu Divestiture - Summary of Income Statement (Details)

v3.20.1
Aytu Divestiture - Summary of Income Statement (Details) - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:    
Income (loss) from discontinued operations, net of tax (inclusive of gain on sale)   $ (4,778,711)
Pediatric Portfolio | Discontinued Operations, Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Product revenue, net $ 10,166,611 11,298,423
Operating expenses:    
Cost of product sales 4,288,234 4,217,594
General and administrative 137,911 165,674
Sales and marketing 8,521,190 7,977,243
Amortization expense 2,425,083 2,703,896
Impairment of intangible assets 1,449,121 0
Change in fair value of contingent consideration 247,042 169,289
Total operating expenses 17,068,581 15,233,696
Interest expense, net (793,860) (827,882)
Gain on sale of Pediatric Portfolio 7,964,924 0
Income (loss) from discontinued operations before tax 269,094 (4,763,155)
Income tax expense 70,888 15,556
Income (loss) from discontinued operations, net of tax (inclusive of gain on sale) $ 198,206 $ (4,778,711)